214 related articles for article (PubMed ID: 2780654)
1. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 303():375-81. PubMed ID: 2780654
[No Abstract] [Full Text] [Related]
2. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
3. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
Aso Y; Akaza H; Kameyama S; Niijima T
Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
[No Abstract] [Full Text] [Related]
4. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
Catalona WJ; Ratliff TL
Surg Annu; 1990; 22():363-78. PubMed ID: 2408170
[No Abstract] [Full Text] [Related]
5. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
Okuno H; Shirahase T; Kihara Y; Arai Y
Hinyokika Kiyo; 1989 Sep; 35(9):1503-7. PubMed ID: 2816616
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
[No Abstract] [Full Text] [Related]
7. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Debruyne FM; van der Meijden AP; Franssen MP
Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
[No Abstract] [Full Text] [Related]
8. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
[TBL] [Abstract][Full Text] [Related]
9. When is a cystectomy necessary in carcinoma in situ?
Herr HW
Prog Clin Biol Res; 1989; 303():511-5. PubMed ID: 2780659
[No Abstract] [Full Text] [Related]
10. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
11. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
[TBL] [Abstract][Full Text] [Related]
12. Intravesical BCG therapy in patients with superficial bladder tumors.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
[No Abstract] [Full Text] [Related]
13. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
14. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
Jakse G
Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Brosman SA
Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
[TBL] [Abstract][Full Text] [Related]
16. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
[TBL] [Abstract][Full Text] [Related]
17. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993).
Oosterlinck W; Kirkali Z; Sylvester R; da Silva FC; Busch C; Algaba F; Collette S; Bono A
Eur Urol; 2011 Mar; 59(3):438-46. PubMed ID: 21156335
[TBL] [Abstract][Full Text] [Related]
18. BCG therapy of superficial bladder tumors.
Herr HW
Prog Clin Biol Res; 1989; 303():369-74. PubMed ID: 2674999
[No Abstract] [Full Text] [Related]
19. Superficial bladder disease: case studies and therapeutic advances.
Soloway MS; Droller MJ; Flanigan RC; Nseyo UO
Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
[No Abstract] [Full Text] [Related]
20. Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder.
Koga H; Kuroda M; Kudo S; Yamaguchi A; Usami M; Suzuki T; Naito S
Int J Urol; 2005 Feb; 12(2):145-51. PubMed ID: 15733108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
